Following adjustment for baseline SBP/DBP (model 1), and for baseline SBP/DBP, newly diagnosed or established hypertension, age, gender, and the presence of diabetes (model 2), compared with ACE-inhibitor treatment, AZL-M treatment was still associated with statistically significant reductions in SBP (p < 0.05 and 0.01 for the two respective models) and DBP (p < 0.05 for both models). Here, ACE is linked to hypertensive disorder.